In Vitro Characterization of Doxorubicin-Mediated Stress-Induced Premature Senescence in Human Chondrocytes.
ROS
SASP
SIPS
aging
chondrocytes
doxorubicin
osteoarthritis
oxidative stress
senescence
uPAR
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
25 03 2022
25 03 2022
Historique:
received:
01
03
2022
revised:
17
03
2022
accepted:
23
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Accumulation of senescent chondrocytes is thought to drive inflammatory processes and subsequent cartilage degeneration in age-related as well as posttraumatic osteoarthritis (OA). However, the underlying mechanisms of senescence and consequences on cartilage homeostasis are not completely understood so far. Therefore, suitable in vitro models are needed to study chondrocyte senescence. In this study, we established and evaluated a doxorubicin (Doxo)-based model of stress-induced premature senescence (SIPS) in human articular chondrocytes (hAC). Cellular senescence was determined by the investigation of various senescence associated (SA) hallmarks including β-galactosidase activity, expression of p16, p21, and SA secretory phenotype (SASP) markers (IL-6, IL-8, MMP-13), the presence of urokinase-type plasminogen activator receptor (uPAR), and cell cycle arrest. After seven days, Doxo-treated hAC displayed a SIPS-like phenotype, characterized by excessive secretion of SASP factors, enhanced uPAR-positivity, decreased proliferation rate, and increased β-galactosidase activity. This phenotype was proven to be stable seven days after the removal of Doxo. Moreover, Doxo-treated hAC exhibited increased granularity and flattened or fibroblast-like morphology. Further analysis implies that Doxo-mediated SIPS was driven by oxidative stress as demonstrated by increased ROS levels and NO release. Overall, we provide novel insights into chondrocyte senescence and present a suitable in vitro model for further studies.
Identifiants
pubmed: 35406671
pii: cells11071106
doi: 10.3390/cells11071106
pmc: PMC8998002
pii:
doi:
Substances chimiques
Doxorubicin
80168379AG
beta-Galactosidase
EC 3.2.1.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Med. 2021 Jun 25;27(1):66
pubmed: 34172007
Antioxidants (Basel). 2020 Mar 23;9(3):
pubmed: 32210013
Med Pharm Rep. 2020 Jan;93(1):12-22
pubmed: 32133442
Biomed Res Int. 2014;2014:648459
pubmed: 24959581
Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8348-52
pubmed: 7667293
Bone Res. 2019 Aug 5;7:23
pubmed: 31646013
Int J Mol Sci. 2019 Sep 10;20(18):
pubmed: 31510091
Sci Transl Med. 2019 Apr 3;11(486):
pubmed: 30944169
Int J Mol Sci. 2020 Mar 29;21(7):
pubmed: 32235300
Osteoarthritis Cartilage. 2020 May;28(5):685-697
pubmed: 31981738
Aging Cell. 2002 Oct;1(1):57-65
pubmed: 12882354
Front Pharmacol. 2021 Aug 23;12:728100
pubmed: 34497523
Free Radic Biol Med. 2019 Feb 20;132:73-82
pubmed: 30176344
J Gerontol A Biol Sci Med Sci. 2004 Apr;59(4):324-37
pubmed: 15071075
Biochem Pharmacol. 1999 Apr 1;57(7):727-41
pubmed: 10075079
Histol Histopathol. 2004 Jan;19(1):105-12
pubmed: 14702177
Nat Rev Immunol. 2013 May;13(5):349-61
pubmed: 23618831
BMB Rep. 2019 Jan;52(1):5-12
pubmed: 30526768
Aging Cell. 2018 Aug;17(4):e12771
pubmed: 29744983
Biogerontology. 2014 Feb;15(1):47-64
pubmed: 24243065
Free Radic Res. 2018 Jan;52(1):92-102
pubmed: 29228832
Trends Cell Biol. 2018 Jun;28(6):436-453
pubmed: 29477613
Cell Mol Immunol. 2018 Feb;15(2):171-181
pubmed: 28090093
PLoS One. 2012;7(5):e37205
pubmed: 22606351
Aging Cell. 2017 Apr;16(2):210-218
pubmed: 28124466
J Orthop Res. 2016 Jan;34(1):135-40
pubmed: 26250350
Osteoarthritis Cartilage. 2015 Nov;23(11):1946-54
pubmed: 26521741
Aging (Albany NY). 2020 Jan 17;12(2):1987-2004
pubmed: 31951594
J Rheumatol. 2002 Oct;29(10):2165-75
pubmed: 12375328
Mol Med Rep. 2013 Oct;8(4):1155-62
pubmed: 23982192
J Rheumatol. 2007 Mar;34(3):556-62
pubmed: 17309123
Int J Biochem Cell Biol. 2012 Sep;44(9):1531-40
pubmed: 22728163
Oxid Med Cell Longev. 2018 Mar 18;2018:7582730
pubmed: 29743983
Osteoarthritis Cartilage. 2009 Aug;17(8):971-9
pubmed: 19303469
FEBS J. 2021 Jan;288(1):56-80
pubmed: 32961620
Nat Rev Rheumatol. 2021 Jan;17(1):47-57
pubmed: 33208917
FEBS J. 2020 Jun;287(12):2418-2427
pubmed: 32112672
Med Sci Monit. 2019 May 16;25:3617-3623
pubmed: 31092810
Mol Oncol. 2021 Aug;15(8):2185-2202
pubmed: 33524223
J Dev Biol. 2015 Dec;3(4):177-192
pubmed: 27347486
Oxid Med Cell Longev. 2018 Feb 11;2018:3075293
pubmed: 29599894
Clin Geriatr Med. 2010 Aug;26(3):355-69
pubmed: 20699159
Arthritis Res Ther. 2005;7(2):R380-91
pubmed: 15743486
Proc Natl Acad Sci U S A. 1988 Dec;85(23):9086-90
pubmed: 3194411
Front Cell Dev Biol. 2021 Jul 14;9:625497
pubmed: 34336816
J Biol Chem. 2004 Jan 16;279(3):2030-7
pubmed: 14570874
Front Cell Dev Biol. 2021 Mar 29;9:645593
pubmed: 33855023
Biogerontology. 2004;5(1):1-10
pubmed: 15138376
J Clin Invest. 2018 Apr 2;128(4):1229-1237
pubmed: 29608139
Cancers (Basel). 2020 May 02;12(5):
pubmed: 32370259
Aging Cell. 2019 Apr;18(2):e12911
pubmed: 30710410
J Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):780-785
pubmed: 27516624
Front Physiol. 2018 Jun 25;9:706
pubmed: 29988615
Toxicology. 2010 May 27;271(3):115-21
pubmed: 20346999
Osteoarthritis Cartilage. 2016 Dec;24(12):2171-2180
pubmed: 27514995
Arthritis Rheum. 2012 Jun;64(6):1697-707
pubmed: 22392533
Int J Mol Sci. 2020 Feb 25;21(5):
pubmed: 32106481
Arthritis Res Ther. 2020 Oct 21;22(1):251
pubmed: 33087182
Curr Rheumatol Rep. 2019 Jun 15;21(8):38
pubmed: 31203465
Aging Cell. 2021 Jan;20(1):e13285
pubmed: 33393189
Cell Death Dis. 2019 Sep 17;10(10):683
pubmed: 31527653